C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data

C4 Therapeutics Inc. (NASDAQ:CCCC) is one of the 11 most popular AI penny stocks to buy now. On February 23, Brookline increased the firm’s price target on C4 Therapeutics Inc. (NASDAQ:CCCC) from $20 to $30, while maintaining its Buy rating on the stock. The price target increase reflects growing conviction following the initiation timing of the Phase 2 cemsidomide/CFT6455 MOMENTUM trial.

Data continues to show cemsidomide’s differentiated safety and tolerability profile, supporting a clear development path for second-line and later patient populations. The firm also noted that the progress further supports expectations for the Phase 1b trial of cemsidomide in combination with elranatamab to begin in the second quarter.

On February 23, C4 Therapeutics Inc. (NASDAQ:CCCC) reported that the first patient had been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. The trial builds on the compelling anti-myeloma activity and differentiated safety profile previously observed in the Phase 1 study.

C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data

Photo by National Cancer Institute on Unsplash

The company noted that initiating the MOMENTUM trial represents an important milestone in advancing cemsidomide as a potential foundational therapy for multiple myeloma patients seeking a safe, oral, and convenient treatment option.

C4 Therapeutics Inc. (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company that is involved in developing novel targeted protein degradation (TPD) therapies. These small-molecule degrader therapies help to cure cancer, multiple myeloma, and other fatal diseases. The company has established several strategic partnerships, including Merck KGaA, Biogen, and Betta Pharmaceuticals.

While we acknowledge the risk and potential of CCCC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CCCC and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.